Ferring Pharmaceuticals

Press Release

Ferring Presents $1,000 to Local Honorable Mention Winner

Jeff Horne, reproductive and endocrine specialist, Ferring Pharmaceuticals, presents Kristi Pelot, honorable mention winner of its My Little Miracle Essay Contest, with a $1,000 prize for her children, Max and Jackson, born with the help of Repronex™ (menotropins for injection, USP) - one of the Company’s fertility treatments.

Pictured from left to right: Jeff Horne, Ferring Pharmaceuticals, Kristi Pelot holding Max, and Eric Scott Sills, M.D., holding Jackson.

ATLANTA – November 23, 2004 – Georgia Reproductive Specialists (GRS) announced today that its patient, Kristi Pelot, received a $1,000 honorable mention prize from Ferring Pharmaceuticals for her entry in the Company’s My Little Miracle Essay Contest. Kristi’s entry, Two Heartbeats, chronicled the path to her sons’ births. The prize money will be deposited into an education fund for Max and Jackson, her twenty-two-month-old sons born with the help of Repronex™ (menotropins for injection, USP) – one of Ferring’s fertility treatments. The presentation was made on November 22nd at GRS’s office in Atlanta.

“I am so thrilled to have been chosen as a winner in the My Little Miracle Essay Contest,” said Kristi Pelot. “We are so pleased that our twin boys have a good start to their educational futures! Thank you, Ferring Pharmaceuticals, for making our dreams of parenthood a reality!”

“Our entire team was elated to hear of yet another success story with Repronex™,” added Eric Scott Sills, M.D., GRS. “The fact that Ferring supports this type of educational fund for the babies conceived with such therapy is commendable.”

The My Little Miracle Essay Contest celebrated the births of children made possible through Ferring’s fertility treatments, Bravelle™ (urofollitropin for injection, purified) and Repronex™ (menotropins for injection, USP). Ferring awarded $25,000 in education funds to 12 winners from around the country.

“Ferring is delighted to offer this program to help fertility patients contribute to their children’s future,” added Jeff Horne, reproductive and endocrine specialist, Ferring Pharmaceuticals. “Ferring is committed to providing patients with safe, effective and affordable fertility treatments. The My Little Miracle Essay Contest is an extension of Ferring’s support of its patients.”

About the Pelots

The Pelots unsuccessfully tried to conceive for three years and endured two early miscarriages before they sought treatment with a fertility specialist. The couple consulted Dr. Sills and began treatment. After one year of various treatment protocols, and in consultation with both Dr. Sills and another center physician, Mark Perloe, M.D., Kristi was prescribed a new treatment protocol with Repronex™. In her essay, Kristi, speaks of their experience:

‘I see one heartbeat … and … two heartbeats!’ said our doctor. ‘I thought one of the eggs had no yolk in it!’ I said. … My husband and I looked at each other incredulously. We were not only pregnant, we were pregnant with twins! A week before, an ultrasound had confirmed our home pregnancy test. One of the eggs had looked healthy, while the other did not. … On the way home from our doctor’s office, I stopped and bought a book on twins. We dubbed ‘Baby B’ the ‘Come-Back Kid,’ and he’s been determined ever since! … Our boys have completely changed our lives, and my husband and I are very proud of every little milestone they reach. … we know [that] we are truly blessed and very thankful for two healthy boys.

About Bravelle™ and Repronex™
Bravelle™ (urofollitropin for injection, purified), a highly purified human-derived follicle-stimulating hormone (hFSH) for infertility treatment, contains 75 IU of FSH and up to two percent LH activity. Bravelle™, administered SC or IM in conjunction with hCG, is indicated for ovulation induction following pituitary suppression. Bravelle™, administered SC in conjunction with hCG, is also indicated for multiple follicular development during ART cycles in patients who have previously received pituitary suppression.

Repronex™ (menotropins for injection, USP) is the only human menopausal gonadotropin (hMG) on the market in the U.S. and is approved for both subcutaneous and intramuscular administration.

Bravelle™ (urofollitropin for injection, purified) and Repronex™, like all gonadotropins, are potent substances capable of causing mild to severe adverse reactions, including ovarian hyperstimulation syndrome (OHSS) (incidence of 6.0% and 3.5%, respectively), with or without pulmonary or vascular complications, in women undergoing therapy for infertility.

Both treatments are marketed by Ferring Pharmaceuticals Inc., a world leader in naturally occurring protein hormones. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe these medications. Like other products for ovarian stimulation, treatment with
Repronex™ and/ or Bravelle™ may result in multiple gestations.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, markets Bravelle™, Repronex™ and Novarel™ (chorionic gonadotropin for injection, USP) in the U.S. to infertility specialists and their patients. The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and infertility. For more information, call 888-337-7464 or visit www.ferringusa.com or www.ferringfertility.com.

About Georgia Reproductive Specialists
Georgia Reproductive Specialists (GRS) leads the region in reproductive research and applies medical science’s most advanced fertility technologies to provide the highest standards of patient-centered, reproductive healthcare. The staff at GRS, including infertility laboratory pioneer Michael Tucker, Ph.D., is focused on providing individualized, innovative solutions for reproductive challenges and infertility, specializing in in vitro fertilization, intracytoplasmic sperm injection and other assisted reproductive technologies. Fellowship-trained reproductive endocrinologists Dr. Susan C. Conway, Dr. Carolyn Kaplan, Dr. Mark Perloe and Dr. Eric Scott Sills, are experts in female and male disorders including polycystic ovary syndrome (PCOS), repeated pregnancy loss, menstrual disorders and azoospermia. GRS has three offices, Atlanta, Alpharetta and Decatur, to conveniently serve patients across Metro Atlanta. For more information about GRS, visit www.ivf.com.

# # #
For full prescribing information for Bravelle™ and/ or Repronex™, please contact Kelly Laban.